Takeda announces U.S. FDA approved the sBLA for VONVENDI

Takeda (TAK) announced that the U.S. Food and Drug Administration, FDA, has approved the supplemental Biologics License Application, sBLA, for VONVENDI, expanding the indication to include routine prophylaxis to reduce the frequency of bleeding episodes in adults with von Willebrand Disease, VWD, including those with Type 1 and 2 disease, and on-demand and perioperative management of bleeding in pediatric patients with VWD. VONVENDI was previously approved for on-demand and perioperative use in adults with VWD and routine prophylactic use in adults with severe Type 3 VWD receiving on-demand therapy.